Safety and Efficacy of PC945 in Combination With Other Antifungal Therapy for the Treatment of Refractory Invasive Pulmonary Aspergillosis

• Status: Not yet recruiting
• Trial end date: 2024-12-31
• Target enrollment: 0
• Participant gender: All

Summary

To assess the efficacy of nebulized PC945 in combination with systemic antifungal therapy for the treatment of refractory IPA

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pulmocide Ltd

Criteria

Inclusion Criteria:

Subject has proven or probable IPA Subject's IPA has an unfavorable response to adequate antifungal therapy

OR:

Stable or disease progression after a subsequent period of at least seven days of adequate antifungal treatment in a subject who was assessed as stable after at least seven days of adequate antifungal thera

Exclusion Criteria:

Subject with possible IPA Subject with non-invasive pulmonary aspergillosis including simple tracheobronchitis, chronic pulmonary aspergillosis, aspergilloma or Allergic bronchopulmonary aspergillosis (ABPA) Subject with extra-pulmonary aspergillus disease (with the exception of those with sinopulmonary aspergillosis only) or disseminated invasive aspergillosis with clinical or radiological manifestations in other organs

-